Estimation of Utilities for Patients with Metastatic Breast Cancer Using Vignette in Japan
Author(s)
Mao Yamaguchi1, Kensuke Moriwaki, BS, MS, PhD2, Kojiro Shimozuma, PhD, MD2;
1Ritsumeikan university, Student, Kusatsu, Japan, 2Ritsumeikan university, kusatsu, Japan
1Ritsumeikan university, Student, Kusatsu, Japan, 2Ritsumeikan university, kusatsu, Japan
OBJECTIVES: To estimate utility values of patients with metastatic triple-negative breast cancer (mTNBC) and disutility due to treatment-related adverse events (AEs) using vignettes with the Japanese general population.
METHODS: Health states were developed that characterize the impact of mTNBC symptoms and AEs on health-related quality of life (HRQL) through a literature review and interviews with clinical experts. Preferences for 10 different health states were investigated, including progression-free status (PFS) for patients with TNBC, six health states with AEs during treatment with PFS, and progression disease (PD). Those utilities of health states were estimated based on the lead-time trade-off (L-TTO) method by using a generalized estimating equations model. The subjects were 300 Japanese general population in total, with 150 in each of the two cities of Tokyo and Osaka.
RESULTS: Mean L-TTO scores for PFS and PD states were 0.702 (95% CI: 0.675~0.730) and 0.583 (95% CI: 0.547~0.618), respectively. Regarding the disutility due to AEs, nausea/vomiting was shown to have the greatest impact on HRQL (-0.936), and neutropenia have the least impact (-0.037).
CONCLUSIONS: This study quantified utility weights and clarified the magnitude of the impact of AEs in Japanese patients with mTNBC. These findings emphasize the importance of considering the decline in HRQL when evaluating the cost-effectiveness of treatments for mTNBC. The data obtained in this study can be used in the future to analyze the cost-effectiveness of various drugs for mTNBC, considering the preferences of the Japanese population, and can also be used to propose the optimal treatment for mTNBC.
METHODS: Health states were developed that characterize the impact of mTNBC symptoms and AEs on health-related quality of life (HRQL) through a literature review and interviews with clinical experts. Preferences for 10 different health states were investigated, including progression-free status (PFS) for patients with TNBC, six health states with AEs during treatment with PFS, and progression disease (PD). Those utilities of health states were estimated based on the lead-time trade-off (L-TTO) method by using a generalized estimating equations model. The subjects were 300 Japanese general population in total, with 150 in each of the two cities of Tokyo and Osaka.
RESULTS: Mean L-TTO scores for PFS and PD states were 0.702 (95% CI: 0.675~0.730) and 0.583 (95% CI: 0.547~0.618), respectively. Regarding the disutility due to AEs, nausea/vomiting was shown to have the greatest impact on HRQL (-0.936), and neutropenia have the least impact (-0.037).
CONCLUSIONS: This study quantified utility weights and clarified the magnitude of the impact of AEs in Japanese patients with mTNBC. These findings emphasize the importance of considering the decline in HRQL when evaluating the cost-effectiveness of treatments for mTNBC. The data obtained in this study can be used in the future to analyze the cost-effectiveness of various drugs for mTNBC, considering the preferences of the Japanese population, and can also be used to propose the optimal treatment for mTNBC.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
MSR117
Topic
Methodological & Statistical Research
Disease
SDC: Oncology